MSH2 and cancer: Although initially classified as a variant of uncertain significance at the time of referral, this variant was subsequently reclassified as likely pathogenic based on its association with MSH2 protein deficiency, MSI, and tumor LOH in multiple individuals with strong personal and family history of Lynch syndrome spectrum cancers.